First Trust NYSE Arca Biotechnology Index Fund (FBT) is a publicly traded the market company. As of May 21, 2026, FBT trades at $204.57 with a market cap of $0 and a P/E ratio of 0.00. FBT moved +2.10% today. Year to date, FBT is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.00 to $0.00. Rallies surfaces FBT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Moderna’s Flu Vaccine Application Accepted with August 5 PDUFA Date: Moderna’s mRNA-1010 flu vaccine biologics license application was accepted for review, with an FDA PDUFA goal date of August 5. Moderna posted a Q4 loss of $2.11 per share on $678 million sales, exceeding estimates.
| Metric | Value |
|---|---|
| Price | $204.57 |
| Market Cap | $0 |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $0.00 |
| 52-Week Low | $0.00 |
| Volume | 112.87K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
FBT analyst coverage data. Average price target: $0.00.